222 filings
Page 9 of 12
8-K
0z0k4vqvp
14 Nov 16
VistaGen Therapeutics Reports Second Quarter 2017 Financial Results and Business Update
12:00am
8-K
ewjjo5zit
21 Oct 16
Regulation FD Disclosure
12:00am
8-K
u0v 7svmo0sye
27 Sep 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
7ersv8vsq7
22 Sep 16
VistaGen Therapeutics Provides Business Outlook
12:00am
8-K
rweift1a8vble
17 Aug 16
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
q8bn3 qk16pk9ea4u4j
22 Jun 16
VistaGen Therapeutics Appoints Pharmaceutical CNS Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer
12:00am
8-K
7qwku
16 May 16
VistaGen Announces Nasdaq Listing and Pricing of $10.0 Million Public Offering
12:00am
8-K
aj4gp8wl2tv7t8tba
30 Mar 16
VistaGen Therapeutics Appoints Jerry Gin, Ph.D., MBA
12:00am
8-K
ntadz16864 9xith4
23 Mar 16
VistaGen Therapeutics Bolsters Clinical and Regulatory Advisory Board with Appointments of Distinguished Key Opinion Leaders in Depression
12:00am
8-K/A
kc8rd
25 Feb 16
Unregistered Sales of Equity Securities
12:00am
8-K
g1f7qpbaec
24 Feb 16
Unregistered Sales of Equity Securities
12:00am
8-K
8zq5m8rf8m00atg
11 Feb 16
Regulation FD Disclosure
12:00am
8-K
m0wksy0l09jus nh
29 Jan 16
Entry into a Material Definitive Agreement
12:00am
8-K
0qjef y6vdrgn6
3 Nov 15
VistaGen Announces First Patient Dosed in NIH-Sponsored Phase 2A Study of Orally Available AV-101 in Major Depressive Disorder
12:00am
8-K
xsl97pm8
18 Sep 15
Pre-clinical Study Results Show Equal Efficacy and Improved Safety Profile Compared with Ketamine
12:00am
8-K
9eybn9yr
25 Aug 15
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
oppiw82nsvcft c0
2 Jul 15
VistaGen Receives FDA and NIH Clearance to Initiate NIH-Funded Phase 2 Study
12:00am
8-K
jucwisn72pr8
16 Jun 15
Entry into a Material Definitive Agreement
12:00am
8-K
jjvs6l ej
22 May 15
Entry into a Material Definitive Agreement
12:00am
8-K
2wlnssbm
13 May 15
Entry into a Material Definitive Agreement
12:00am